Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5fe2o3.9h2o
2. Ferric Hydroxide Oxide
3. Ferric Hydroxide Oxide (feooh)
4. Ferric Oxy-hydroxide
5. Ferric Oxyhydroxide (feo2h)
6. Ferrihydrite
7. Iron Hydroxide Oxide (fe(oh)o)
8. Iron Hydroxide Oxide (feo(oh))
9. Iron(iii) Oxyhydroxide
1. Iron Hydroxide Oxide
2. Iron(3+);oxygen(2-);hydroxide
3. Iron Hydroxide Oxide Nanoparticles / Nanopowder
4. Iron Oxide Hydroxide
5. Iron Hydroxide Nanorods
6. Ferric Oxy-hydroxide
7. Ferric Hydroxide [mi]
8. Dtxsid3042057
9. Ferric Oxyhydroxide (feo2h)
10. Ferric Hydroxide Oxide (feooh)
11. Db14695
12. Iron Hydroxide Oxide (feo(oh))
13. Iron Oxide Hydroxide, Aqueous Nanoparticle Dispersion, <5 Nm (dls), 20% Solids By Weight, Ph ~3, 99.5% Trace Metals Basis
1. Feojectin
2. Ferplex Ss
3. Ferrivenin
4. Iviron
5. Proferrin
6. Sucrofer
7. Iron Sugar
8. Saccharated Iron
9. Venoferrum
10. Fesin
11. Ferrum Vitis
12. Hippiron
13. Ferum Hausmann
Molecular Weight | 88.85 g/mol |
---|---|
Molecular Formula | FeHO2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 88.932590 g/mol |
Monoisotopic Mass | 88.932590 g/mol |
Topological Polar Surface Area | 2 Ų |
Heavy Atom Count | 3 |
Formal Charge | 0 |
Complexity | 0 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
2 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-04
Pay. Date : 2016-07-14
DMF Number : 28865
Submission : 2016-07-07
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm :
Available Reg Filing : BR |
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33643
Submission : 2019-03-30
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Date of Issue : 2022-05-27
Valid Till : 2025-05-20
Written Confirmation Number : WC-0001A2
Address of the Firm :
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34957
Submission : 2020-06-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-10
Pay. Date : 2023-09-28
DMF Number : 38610
Submission : 2023-07-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31315
Submission : 2017-01-03
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-04-26
Pay. Date : 2019-02-19
DMF Number : 33020
Submission : 2018-08-09
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm : CTO-SEZ-Process Unit-01, Sector No 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Date of Issue : 2022-05-27
Valid Till : 2025-05-20
Written Confirmation Number : WC-0001A2
Address of the Firm : Q-1-4,Industrial area ,Ghinrongi Malanpur -477 117, Dist -Bhind (MP)
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Sy.No.1/22, 2/1 To 5, 6 to 18, 61 to 69, Pydibhimavaram Village, Ranasthalam, Sr...
Iron Sucrose Complex IH, Complex Solution
Date of Issue : 2019-10-07
Valid Till : 2022-07-02
Written Confirmation Number : WC-0226
Address of the Firm : D-24 and D24/1 MIDC Kurkumbh Tal. Daund, Dist Pune 413 802, Maharashtra State
Iron Sucrose IH/Iron Sucrose liquid IH
Date of Issue : 2020-02-10
Valid Till : 2022-02-02
Written Confirmation Number : WC-0356
Address of the Firm : Block C, Phase-I Visakhapatnam Special Economic Zone, Andhra Pradesh, India
Date of Issue : 2022-06-07
Valid Till : 2025-06-16
Written Confirmation Number : WC-0049
Address of the Firm : Block 21, Dabhasa, Padra Taluka, Vadodara-391 440
Date of Issue : 2020-07-23
Valid Till : 2023-05-11
Written Confirmation Number : WC-0273
Address of the Firm : Plot No. 34A, J.N.Pharma City, Thanam (V), Parawada (M), Vishakhapatnam-District...
Date of Issue : 2020-03-18
Valid Till : 2020-05-11
Written Confirmation Number : WC-0273A7
Address of the Firm : Plot No. 34A, J.N.Pharma City, Thanam (V), Parawada (M), Vishakhapatnam-District...
Iron sucrose (Pyrogen Free) IH
Date of Issue : 2020-06-05
Valid Till : 2022-10-22
Written Confirmation Number : WC-0454
Address of the Firm : Plot No. 5 to 16, Survey No. 137, At & Post: Padavala, Ta-Kotda Sangani, Dist-Ra...
Date of Issue : 2019-07-15
Valid Till : 2022-07-14
Written Confirmation Number : WC-0042
Address of the Firm : Plot No.262, 263, IDA, Pashamylaram, Medak District, A.P
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
NDC Package Code : 64552-4065
Start Marketing Date : 2013-11-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-056
Start Marketing Date : 2017-10-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76339-166
Start Marketing Date : 2023-11-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (4.999kg/4.999kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0153
Start Marketing Date : 2013-11-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62991-3199
Start Marketing Date : 2024-07-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82592-2202
Start Marketing Date : 2022-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76055-0038
Start Marketing Date : 2019-07-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68022-7510
Start Marketing Date : 2016-02-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 68022-7032
Start Marketing Date : 2024-01-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 66022-0302
Start Marketing Date : 2013-11-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Announces Publication Of Results from Phase 2 Study Evaluating RBT-1
Details : RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surg...
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2023
Details:
The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Juniper Point
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 12, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Juniper Point
Deal Size : $72.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iro...
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Undisclosed
September 12, 2023
Details:
The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 18, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $47.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surg...
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2023
Details:
RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Details:
Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Brand Name: Velphoro
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
VFMCRP Announces U.S. Court Upholds Validity of Velphoro® Patent
Details : Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Product Name : Velphoro
Product Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Details:
RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2022
Details:
Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 15, 2022
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $35.0 million
Deal Type : Series A Financing
Details : Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a ...
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Undisclosed
February 15, 2022
Details:
This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
Details : This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Product Name : RBT-1
Product Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2021
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 426,893,782
Year : 2022
Prescribers : 33445
Prescriptions : 139368
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Iron Sucrose Complex
Drug Cost (USD) : 5,736
Year : 2022
Prescribers : 12
Prescriptions : 16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 380,608,096
Year : 2021
Prescribers : 30774
Prescriptions : 126367
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 343,032,075
Year : 2020
Prescribers : 29839
Prescriptions : 123235
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 240,049,327
Year : 2019
Prescribers : 27060
Prescriptions : 98561
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 139,257,257
Year : 2018
Prescribers : 17789
Prescriptions : 59836
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 93,942,359
Year : 2017
Prescribers : 12065
Prescriptions : 42676
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 71,897,800
Year : 2016
Prescribers : 11044
Prescriptions : 39708
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Sucroferric Oxyhydroxide
Drug Cost (USD) : 43,010,787
Year : 2015
Prescribers : 8369
Prescriptions : 29402
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
SUCROFERRIC OXYHYDROXIDE
Drug Cost (USD) : 13,437,502
Year : 2014
Prescribers : 4130
Prescriptions : 10437
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
38
PharmaCompass offers a list of Sucroferric Oxyhydroxide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sucroferric Oxyhydroxide manufacturer or Sucroferric Oxyhydroxide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sucroferric Oxyhydroxide manufacturer or Sucroferric Oxyhydroxide supplier.
PharmaCompass also assists you with knowing the Sucroferric Oxyhydroxide API Price utilized in the formulation of products. Sucroferric Oxyhydroxide API Price is not always fixed or binding as the Sucroferric Oxyhydroxide Price is obtained through a variety of data sources. The Sucroferric Oxyhydroxide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ferric oxyhydroxide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ferric oxyhydroxide, including repackagers and relabelers. The FDA regulates Ferric oxyhydroxide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ferric oxyhydroxide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ferric oxyhydroxide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ferric oxyhydroxide supplier is an individual or a company that provides Ferric oxyhydroxide active pharmaceutical ingredient (API) or Ferric oxyhydroxide finished formulations upon request. The Ferric oxyhydroxide suppliers may include Ferric oxyhydroxide API manufacturers, exporters, distributors and traders.
click here to find a list of Ferric oxyhydroxide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ferric oxyhydroxide DMF (Drug Master File) is a document detailing the whole manufacturing process of Ferric oxyhydroxide active pharmaceutical ingredient (API) in detail. Different forms of Ferric oxyhydroxide DMFs exist exist since differing nations have different regulations, such as Ferric oxyhydroxide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ferric oxyhydroxide DMF submitted to regulatory agencies in the US is known as a USDMF. Ferric oxyhydroxide USDMF includes data on Ferric oxyhydroxide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ferric oxyhydroxide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ferric oxyhydroxide suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ferric oxyhydroxide Drug Master File in Korea (Ferric oxyhydroxide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ferric oxyhydroxide. The MFDS reviews the Ferric oxyhydroxide KDMF as part of the drug registration process and uses the information provided in the Ferric oxyhydroxide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ferric oxyhydroxide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ferric oxyhydroxide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ferric oxyhydroxide suppliers with KDMF on PharmaCompass.
A Ferric oxyhydroxide written confirmation (Ferric oxyhydroxide WC) is an official document issued by a regulatory agency to a Ferric oxyhydroxide manufacturer, verifying that the manufacturing facility of a Ferric oxyhydroxide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ferric oxyhydroxide APIs or Ferric oxyhydroxide finished pharmaceutical products to another nation, regulatory agencies frequently require a Ferric oxyhydroxide WC (written confirmation) as part of the regulatory process.
click here to find a list of Ferric oxyhydroxide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ferric oxyhydroxide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ferric oxyhydroxide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ferric oxyhydroxide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ferric oxyhydroxide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ferric oxyhydroxide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ferric oxyhydroxide suppliers with NDC on PharmaCompass.
Ferric oxyhydroxide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ferric oxyhydroxide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ferric oxyhydroxide GMP manufacturer or Ferric oxyhydroxide GMP API supplier for your needs.
A Ferric oxyhydroxide CoA (Certificate of Analysis) is a formal document that attests to Ferric oxyhydroxide's compliance with Ferric oxyhydroxide specifications and serves as a tool for batch-level quality control.
Ferric oxyhydroxide CoA mostly includes findings from lab analyses of a specific batch. For each Ferric oxyhydroxide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ferric oxyhydroxide may be tested according to a variety of international standards, such as European Pharmacopoeia (Ferric oxyhydroxide EP), Ferric oxyhydroxide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ferric oxyhydroxide USP).